On 31 July 2018, orphan designation (EU/3/18/2044) was granted by the European Commission to medac Gesellschaft für klinische Spezialpräparate mbH, Germany, for allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded for the treatment of graft-versus-host disease.
Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded
|Disease / condition||
Treatment of graft-versus-host disease
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active
- Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe.